文献速递衰弱、肌少症与跌倒老年综合评估

早期实体瘤老年患者衰弱筛查:三种老年评估工具的前瞻性纵向评价

Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2017-01-01

本研究纳入185例70岁及以上早期实体瘤患者,分别用Balducci衰弱标准(BFC)、Fried衰弱标准(FFC)和脆弱老年人调查-13(VES-13≥7分)判定衰弱,并随访功能衰退与死亡。三种工具衰弱率分别为17%(FFC)和25%(BFC与VES-13),一致性差;FFC与VES-13对功能衰退判别力强,BFC对死亡判别力最高,BFC与VES-13在多变量分析中仍为总生存的预后因素。

要点

  • VES-13≥7分可判别功能衰退或死亡风险,适合资源有限中心作衰弱筛查。
  • BFC、FFC与VES-13判定衰弱的一致性差,衰弱率分别为25%、17%、25%。
  • BFC对死亡判别力最高(HR=3.29),FFC与VES-13对功能衰退判别力强。

核心结论

  • VES-13≥7分是预测功能衰退或死亡的有价值判别工具,可在资源有限中心作为老年癌症患者的衰弱筛查工具。

研究设计与样本

  • 前瞻性纵向研究,纳入185例70岁及以上早期实体瘤患者,按BFC(≥1条标准)、FFC(≥3条标准)和VES-13(≥7分)分类为衰弱/非衰弱,并评估功能衰退与死亡。

主要发现

  • FFC衰弱率为17%,BFC和VES-13均为25%,三种工具间一致性差。
  • FFC(HR=1.99,p=.003)和VES-13(HR=2.81,p<.001)对功能衰退有强判别力。
  • BFC对死亡判别率最高(HR=3.29,p<.001)。
  • 校正年龄、肿瘤类型、分期和全身治疗后,BFC和VES-13仍为总生存的预后因素。

关键数值与推荐

  • BFC衰弱判定:≥1条标准;FFC衰弱判定:≥3条标准;VES-13衰弱判定:评分≥7分。

临床怎么用

  • 在资源有限、难以开展老年综合评估的中心,可用VES-13≥7分筛查早期实体瘤老年患者的衰弱,以预测功能衰退或死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty increases the risk of adverse health outcomes and/or dying when exposed to a stressor, and routine frailty assessment is recommended to guide treatment decision. The Balducci frailty criteria (BFC) and Fried frailty criteria (FFC) are commonly used, but these are time consuming. Vulnerable Elders Survey-13 (VES-13) score of ≥7, a simple and resource conserving function-based scoring system, may be used instead. This prospective study evaluates the performance of VES-13 in parallel with BFC and FFC, to identify frailty in elderly patients with early-stage cancer. METHODS: Patients aged ≥70 years with early-stage solid tumors were classified as frail/nonfrail based on BFC (≥1 criteria), FFC (≥3 criteria), and VES-13 (score ≥ 7). All patients were assessed for functional decline and death. RESULTS: We evaluated 185 patients. FFC had a 17% frailty rate, whereas BFC and VES-13 both had 25%, with poor concordance seen between the three geriatric tools. FFC (hazard ratio = 1.99, p = .003) and VES-13 (hazard ratio = 2.81, p < .001) strongly discriminated for functional decline, whereas BFC (hazard ratio = 3.29, p < .001) had the highest discriminatory rate for deaths. BFC and VES-13 remained prognostic for overall survival in multivariate analysis correcting for age, tumor type, stage, and systemic treatment. CONCLUSIONS: A VES-13 score of ≥7 is a valuable discriminating tool for predicting functional decline or death and can be used as a frailty-screening tool among older cancer patients in centers with limited resources to conduct a comprehensive geriatric assessment.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Biganzoli L, Mislang AR, Di Donato S, et al. Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools. J Gerontol A Biol Sci Med Sci. 2017. PMID: 28158486. doi:10.1093/gerona/glw234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。